Market Research Logo

Paediatric Vaccine Market: Pneumococcal Indication Segment Anticipated to Be the Most Attractive Segment Through 2026: Global Industry Analysis and Opportunity Assessment, 2016-2026

Paediatric Vaccine Market: Pneumococcal Indication Segment Anticipated to Be the Most Attractive Segment Through 2026: Global Industry Analysis and Opportunity Assessment, 2016-2026

Global Paediatric Vaccine Market: Towards a better and safer tomorrow

Paediatric vaccines are administered to a child in its paediatric age which is from 0 – 18 years of age. Vaccines are generally given in order to prevent children from diseases transferred through infections, seasonal variations and even through unhygienic areas. Depending upon disease, the vaccines are administered at regular intervals. WHO has designed a standard immunization program in order to have desired time interval between vaccines doses.

Paediatric vaccines considered in the report include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. Pneumococcal vaccine is administered to prevent the child from infectious diseases such as pneumonia. DTP vaccines is a combination vaccine administered against prevention of three diseases those are diphtheria, tetanus and pertussis. Hib vaccine is also a combination vaccine for hepatitis B and influenza and is widely accepted.

The market to expand manifold during the forecast period (2016 - 2026)

In terms of revenue, the global paediatric vaccine market is projected to expand at a CAGR of 12.2% during the forecast period and is expected to be valued at US$ 88.14 Bn by the end of 2026.

Revamped government policies to benefit the market, though soaring prices of vaccines to play spoilsport

The growth of the global paediatric vaccine market is primarily driven by increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines. In addition favourable reimbursement and increasing government support is expected to fuel the market growth over the forecast period. However, rising cost of vaccines, low accessibility to remote areas and increasing the availability of biosimilars at low rates might hinder the market growth over the forecast period.

The Pneumococcal segment to act as a catalyst in the overall market growth

Based on indication, the global paediatric vaccine market is segmented into pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. In terms of revenue share, the pneumococcal segment dominated the global paediatric vaccine market in 2015 and is expected to reach the cusp within the forecast period. The Hib segment is expected to witness relatively higher growth rates in terms of value in the global paediatric vaccine market over the forecast period.

Recombinant segment to face steep competition from the Conjugate segment within the forecast period

Based on technology, the global paediatric vaccine market is segmented into live or attenuated vaccine, inactivated or killed vaccines, conjugate vaccine, toxoid vaccine, subunit vaccine and recombinant vaccine. In terms of revenue share, the conjugate segment dominated the global paediatric vaccine market in 2015 and is expected to maintain the spike throughout the forecast period, registering higher CAGR as compared to the recombinant segment.

Monovalent vaccine segment to accumulate maximum market share

Based on vaccine type, the global paediatric vaccine market is segmented into monovalent vaccines and multivalent vaccines. Among these, monovalent vaccine segment held maximum market share in 2015 and expected to continue the trend throughout the forecast period.

The Institutional Health Centres segment to topple Hospital Pharmacy segment in the forecast period

Based on end user, the global paediatric vaccine market is segmented into hospital pharmacies, retail pharmacies and institutional health centres. Currently, institutional health centres segment accounts for relatively higher revenue share, followed by hospital pharmacy end user segment.

paediatric vaccine market_Image for preview analysis

North America market to lead the pack

The global paediatric vaccine market is segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, APEJ (Asia Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America is expected to be the dominant regional market by 2016 end and is expected to expand at a CAGR of 11.0% over the forecast period. APEJ is expected to be the fastest growing market in terms of revenue growth in the global paediatric vaccine market, registering a CAGR of 14.9% over the forecast period.

Key stakeholders to create clamour in the market through mergers and revamped investment policies

Some key players in the global paediatric vaccine market included in this report are GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Panacea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immunologicals Ltd.


1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
2.3. Parent / Associated Market Overview
3. Global Paediatric Vaccine Market Analysis Scenario
3.2. Market Size (US$ Mn) and Forecast
3.2.1. Market Size and Y-o-Y Growth
3.2.2. Absolute $ Opportunity
3.3. Market Overview
3.3.1. Value Chain
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
4.5. Forecast Factors – Relevance and Impact
4.6. Key Industry Events
4.7. PESTLE Analysis
5. Global Paediatric Vaccine Market Analysis and Forecasts, By Indication
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Indication Type
5.3. Y-o-Y Growth Projections By Indication Type
5.4. Market Value (US$ Mn) Forecast By Indication, 2016–2026
5.4.1. Pneumococcal vaccine
5.4.2. DTP vaccine
5.4.3. Rotavirus vaccine
5.4.4. MMR vaccine
5.4.5. Polio vaccine
5.4.6. Influenza vaccine
5.4.7. Hepatitis B vaccine
5.4.8. Meningococcal vaccine
5.4.9. Hib vaccine
5.4.10. Varicella vaccine
5.5. Prominent Trends
5.6. Market Attractiveness By Indication
6. Global Paediatric Vaccine Market Analysis and Forecasts, By Technology
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Technology
6.3. Y-o-Y Growth Projections By Technology
6.4. Market Value (US$ Mn) Forecast By Technology, 2016–2026
6.4.1. Live or attenuated vaccine
6.4.1.6. Inactivated or killed vaccine
6.4.2.3. Toxoid vaccine
6.4.3.3. Conjugate Vaccine
6.4.4.3. Subunit vaccine
6.4.4.4. Recombinant vaccine
6.5. Prominent Trends
6.6. Market Attractiveness By Technology
7. Global Paediatric Vaccine Market Analysis and Forecasts, By Vaccine Type
7.1. Introduction
7.2. Basis Point Share (BPS) Analysis By Vaccine Type
7.3. Y-o-Y Growth Projections By Vaccine Type
7.4. Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
7.4.1. Monovalent vaccine
7.4.2. Mulitvalent vaccine
7.5. Prominent Trends
7.6. Market Attractiveness By Vaccine Type
8. Global Paediatric Vaccine Market Analysis and Forecasts, By End Users
8.1. Introduction
8.2. Basis Point Share (BPS) Analysis By End Users
8.3. Y-o-Y Growth Projections By End Users
8.4. Market Value (US$ Mn) Forecast By End Users, 2016–2026
8.4.1. Hospital Pharmacies
8.4.2. Retail pharmacies
8.4.3. Institutional health centers
8.5. Prominent Trends
8.6. Market Attractiveness By End Users
9. Global Paediatric Vaccine Market Analysis and Forecasts, By Region
9.1. Basis Point Share (BPS) Analysis By Region
9.2. Y-o-Y Growth Projections By Region
9.3. Market Value (US$ Mn) Forecast By Region
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. APEJ
9.3.6. Japan
9.3.7. MEA
9.4. Market Attractiveness By Region
10. North America Paediatric Vaccine Market Analysis and Forecast
10.1.Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
10.2.1. Pneumococcal vaccine
10.2.2. DTP vaccine
10.2.3. Rotavirus vaccine
10.2.4. MMR vaccine
10.2.5. Polio vaccine
10.2.6. Influenza vaccine
10.2.7. Hepatitis B vaccine
10.2.8. Meningococcal vaccine
10.2.9. Hib vaccine
10.2.10. Varicella vaccine
10.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026
10.3.1. Live or attenuated vaccine
10.3.1.1. Inactivated or killed vaccine
10.3.1.2. Toxoid vaccine
10.3.1.3. Conjugate Vaccine
10.3.1.4. Subunit vaccine
10.3.1.5. Recombinant vaccine
10.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
10.4.1. Monovalent vaccine
10.4.2. Mulitvalent vaccine
10.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
10.5.1. Hospital Pharmacies
10.5.2. Retail pharmacies
10.5.3. Institutional health centers
10.6.Market Value (US$ Mn) Forecast By Country, 2016–2026
10.6.1. US
10.6.2. Canada
10.7.Market Attractiveness Analysis
10.7.1. By Indication
10.7.2. By Technology
10.7.3. By Vaccine Type
10.7.4. By End Users
10.7.5. By Country
10.8. Prominent Trends
10.9. Drivers and Restraints: Impact Analysis
11. Latin America Paediatric Vaccine Market Analysis and Forecast
11.1.Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.1.3. Key Regulations
11.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
11.2.1. Pneumococcal vaccine
11.2.2. DTP vaccine
11.2.3. Rotavirus vaccine
11.2.4. MMR vaccine
11.2.5. Polio vaccine
11.2.6. Influenza vaccine
11.2.7. Hepatitis B vaccine
11.2.8. Meningococcal vaccine
11.2.9. Hib vaccine
11.2.10. Varicella vaccine
11.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026
11.3.1. Live or attenuated vaccine
11.3.1.1. Inactivated or killed vaccine
11.3.1.2. Toxoid vaccine
11.3.1.3. Conjugate Vaccine
11.3.1.4. Subunit vaccine
11.3.1.5. Recombinant vaccine
11.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
11.4.1. Monovalent vaccine
11.4.2. Mulitvalent vaccine
11.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
11.5.1. Hospital Pharmacies
11.5.2. Retail pharmacies
11.5.3. Institutional health centers
11.6.Market Value (US$ Mn) Forecast By Country, 2016–2026
11.6.1. Brazil
11.6.2. Mexico
11.6.3. Rest of Latin America
11.7.Market Attractiveness Analysis
11.7.1. By Indication
11.7.2. By Technology
11.7.3. By Vaccine Type
11.7.4. By End Users
11.7.5. By Country
11.8. Prominent Trends
11.9. Drivers and Restraints: Impact Analysis
12. Western Europe Paediatric Vaccine Market Analysis and Forecast
12.1.Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.1.3. Key Regulations
12.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
12.2.1. Pneumococcal vaccine
12.2.2. DTP vaccine
12.2.3. Rotavirus vaccine
12.2.4. MMR vaccine
12.2.5. Polio vaccine
12.2.6. Influenza vaccine
12.2.7. Hepatitis B vaccine
12.2.8. Meningococcal vaccine
12.2.9. Hib vaccine
12.2.10. Varicella vaccine
12.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026
12.3.1. Live or attenuated vaccine
12.3.1.1. Inactivated or killed vaccine
12.3.1.2. Toxoid vaccine
12.3.1.3. Conjugate Vaccine
12.3.1.4. Subunit vaccine
12.3.1.5. Recombinant vaccine
12.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
12.4.1. Monovalent vaccine
12.4.2. Mulitvalent vaccine
12.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
12.5.1. Hospital Pharmacies
12.5.2. Retail pharmacies
12.5.3. Institutional health centers
12.6.Market Value (US$ Mn) Forecast By Country, 2016–2026
12.6.1. UK
12.6.2. France
12.6.3. Germany
12.6.4. Italy
12.6.5. Spain
12.6.6. Benelux
12.6.7. Rest of Western Europe
12.7.Market Attractiveness Analysis
12.7.1. By Indication
12.7.2. By Technology
12.7.3. By Vaccine Type
12.7.4. By End Users
12.7.5. By Country
12.8. Prominent Trends
12.9. Drivers and Restraints: Impact Analysis
13. Eastern Europe Paediatric Vaccine Market Analysis and Forecast
13.1.Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.1.3. Key Regulations
13.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
13.2.1. Pneumococcal vaccine
13.2.2. DTP vaccine
13.2.3. Rotavirus vaccine
13.2.4. MMR vaccine
13.2.5. Polio vaccine
13.2.6. Influenza vaccine
13.2.7. Hepatitis B vaccine
13.2.8. Meningococcal vaccine
13.2.9. Hib vaccine
13.2.10. Varicella vaccine
13.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026
13.3.1. Live or attenuated vaccine
13.3.1.1. Inactivated or killed vaccine
13.3.1.2. Toxoid vaccine
13.3.1.3. Conjugate Vaccine
13.3.1.4. Subunit vaccine
13.3.1.5. Recombinant vaccine
13.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
13.4.1. Monovalent vaccine
13.4.2. Mulitvalent vaccine
13.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
13.5.1. Hospital Pharmacies
13.5.2. Retail pharmacies
13.5.3. Institutional health centers
13.6.Market Value (US$ Mn) Forecast By Country, 2016–2026
13.6.1. Russia
13.6.2. Poland
13.6.3. Rest of Eastern Europe
13.7.Market Attractiveness Analysis
13.7.1. By Indication
13.7.2. By Technology
13.7.3. By Vaccine Type
13.7.4. By End Users
13.7.5. By Country
13.8. Prominent Trends
13.9. Drivers and Restraints: Impact Analysis
14. APEJ Paediatric Vaccine Market Analysis and Forecast
14.1.Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.1.3. Key Regulations
14.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
14.2.1. Pneumococcal vaccine
14.2.2. DTP vaccine
14.2.3. Rotavirus vaccine
14.2.4. MMR vaccine
14.2.5. Polio vaccine
14.2.6. Influenza vaccine
14.2.7. Hepatitis B vaccine
14.2.8. Meningococcal vaccine
14.2.9. Hib vaccine
14.2.10. Varicella vaccine
14.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026
14.3.1. Live or attenuated vaccine
14.3.1.1. Inactivated or killed vaccine
14.3.1.2. Toxoid vaccine
14.3.1.3. Conjugate Vaccine
14.3.1.4. Subunit vaccine
14.3.1.5. Recombinant vaccine
14.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
14.4.1. Monovalent vaccine
14.4.2. Mulitvalent vaccine
14.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
14.5.1. Hospital Pharmacies
14.5.2. Retail pharmacies
14.5.3. Institutional health centers
14.6.Market Value (US$ Mn) Forecast By Country, 2016–2026
14.6.1. China
14.6.2. India
14.6.3. Australia & New Zealand
14.6.4. ASEAN
14.6.5. Rest of APEJ
14.7.Market Attractiveness Analysis
14.7.1. By Indication
14.7.2. By Technology
14.7.3. By Vaccine Type
14.7.4. By End Users
14.7.5. By Country
14.8. Prominent Trends
14.9. Drivers and Restraints: Impact Analysis
15. Japan Paediatric Vaccine Market Analysis and Forecast
15.1.Introduction
15.1.1. Basis Point Share (BPS) Analysis By Country
15.1.2. Y-o-Y Growth Projections By Country
15.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
15.2.1. Pneumococcal vaccine
15.2.2. DTP vaccine
15.2.3. Rotavirus vaccine
15.2.4. MMR vaccine
15.2.5. Polio vaccine
15.2.6. Influenza vaccine
15.2.7. Hepatitis B vaccine
15.2.8. Meningococcal vaccine
15.2.9. Hib vaccine
15.2.10. Varicella vaccine
15.3.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
15.3.1. Live or attenuated vaccine
15.3.1.1. Inactivated or killed vaccine
15.3.1.2. Toxoid vaccine
15.3.1.3. Conjugate Vaccine
15.3.1.4. Subunit vaccine
15.3.1.5. Recombinant vaccine
15.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
15.4.1. Monovalent vaccine
15.4.2. Mulitvalent vaccine
15.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
15.5.1. Hospital Pharmacies
15.5.2. Retail pharmacies
15.5.3. Institutional health centers
15.6.Market Attractiveness Analysis
15.6.1. By Indication
15.6.2. By Vaccine Type
15.6.3. By Vaccine Type
15.6.4. By End Users
15.7. Prominent Trends
15.8. Drivers and Restraints: Impact Analysis
16. MEA Paediatric Vaccine Market Analysis and Forecast
16.1.Introduction
16.1.1. Basis Point Share (BPS) Analysis By Country
16.1.2. Y-o-Y Growth Projections By Country
16.1.3. Key Regulations
16.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026
16.2.1. Pneumococcal vaccine
16.2.2. DTP vaccine
16.2.3. Rotavirus vaccine
16.2.4. MMR vaccine
16.2.5. Polio vaccine
16.2.6. Influenza vaccine
16.2.7. Hepatitis B vaccine
16.2.8. Meningococcal vaccine
16.2.9. Hib vaccine
16.2.10. Varicella vaccine
16.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026
16.3.1. Live or attenuated vaccine
16.3.1.1. Inactivated or killed vaccine
16.3.1.2. Toxoid vaccine
16.3.1.3. Conjugate Vaccine
16.3.1.4. Subunit vaccine
16.3.1.5. Recombinant vaccine
16.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026
16.4.1. Monovalent vaccine
16.4.2. Mulitvalent vaccine
16.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026
16.5.1. Hospital Pharmacies
16.5.2. Retail pharmacies
16.5.3. Institutional health centers
16.6.Market Value (US$ Mn) Forecast By Country, 2016–2026
16.6.1. GCC Countries
16.6.2. South Africa
16.6.3. Rest of MEA
16.7.Market Attractiveness Analysis
16.7.1. By Indication
16.7.2. By Technology
16.7.3. By Vaccine Type
16.7.4. By End Users
16.7.5. By Country
16.8. Prominent Trends
16.9. Drivers and Restraints: Impact Analysis
17. Competition Landscape
17.1. Competition Dashboard
17.2. Market Share Analysis By Company (2015)
17.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
17.3.1. GlaxoSmithKline Plc.
17.3.2. Merck & Co., Inc.
17.3.3. Pfizer Inc.
17.3.4. Sanofi
17.3.5. Pancea Biotec
17.3.6. Zydua Cadila
17.3.7. Emergent BioSolutions Inc.
17.3.8. Serum Institute of India Pvt. Ltd.
17.3.9. Bharat Biotech
17.3.10. Indian Immunologicals Ltd.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report